Rathod Krishnaraj S, Jones Daniel A, Bromage Daniel I, Gallagher Sean M, Rathod Vrijraj S, Kennon Simon, Knight Charles, Rothman Martin T, Mathur Anthony, Smith Elliot, Jain Ajay K, Archbold R Andrew, Wragg Andrew
aDepartment of Cardiology, London Chest Hospital bDepartment of Clinical Pharmacology, William Harvey Research Institute, Queen Mary University cNIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London, UK.
J Cardiovasc Med (Hagerstown). 2015 Mar;16(3):170-7. doi: 10.2459/JCM.0000000000000230.
To compare long-term clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI) using radial and femoral arterial access.
The present study was an observational cohort study of patients with STEMI treated consecutively with PPCI between 2004 and 2011 at a single centre. The primary end point was all-cause mortality at a median follow-up of 3 years.Among 2727 patients, 1600 (58.7%) underwent PPCI via the femoral route. The femoral group was older (64.7 vs. 61.7 years; P < 0.0001), and had higher rates of diabetes (18.6% vs. 16.0%; P < 0.0001), previous PCI (11.2 vs. 7.8%; P = 0.004), previous myocardial infarction (15.3 vs. 8.3%; P < 0.0001) and cardiogenic shock (9.8 vs. 1.3%; P < 0.0001). Bleeding complications were more frequent in the femoral group (4.7 vs. 1.2%; P < 0.0001). The 5-year death rate was significantly higher in the femoral group than in the radial group (10.4 vs. 3.0%; P < 0.0001). After adjustment for confounding variables, bleeding complications [heart rate 2.07 (95% confidence interval 1.05-4.08)] and femoral access [heart rate 1.60 (95% confidence interval 1.02-2.53)] were independent predictors of all-cause mortality. After stratification using the propensity score, excess long-term mortality in patients treated via the femoral approach was predominantly in patients with a high baseline risk of death.
Patients undergoing PPCI via the femoral route are at a higher risk of adverse short-term and long-term outcomes than patients undergoing PPCI via the radial route. Patients with a high baseline risk may benefit most from radial access, and future outcome studies should focus on the most at-risk patients.
比较经桡动脉和股动脉途径行直接经皮冠状动脉介入治疗(PPCI)的ST段抬高型心肌梗死(STEMI)患者的长期临床结局。
本研究是一项对2004年至2011年在单一中心连续接受PPCI治疗的STEMI患者进行的观察性队列研究。主要终点是在中位随访3年时的全因死亡率。在2727例患者中,1600例(58.7%)经股动脉途径行PPCI。股动脉组患者年龄更大(64.7岁对61.7岁;P<0.0001),糖尿病发生率更高(18.6%对16.0%;P<0.0001),既往PCI史比例更高(11.2%对7.8%;P=0.004),既往心肌梗死比例更高(15.3%对8.3%;P<0.0001),心源性休克发生率更高(9.8%对1.3%;P<0.0001)。股动脉组出血并发症更常见(4.7%对1.2%;P<0.0001)。股动脉组5年死亡率显著高于桡动脉组(10.4%对3.0%;P<0.0001)。在对混杂变量进行调整后,出血并发症[心率2.07(95%置信区间1.05 - 4.08)]和股动脉途径[心率1.60(95%置信区间1.02 - 2.53)]是全因死亡率的独立预测因素。在使用倾向评分进行分层后,经股动脉途径治疗的患者长期死亡率过高主要见于基线死亡风险高的患者。
与经桡动脉途径行PPCI的患者相比,经股动脉途径行PPCI的患者发生不良短期和长期结局的风险更高。基线风险高的患者可能从桡动脉途径中获益最大,未来的结局研究应关注风险最高的患者。